Identification of prognostic markers by weighted gene co‐expression network analysis in non-small cell lung cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Wood SL, Pernemalm M, Crosbie PA, et al. Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev. 2015;41(4):361–375.
   PubMed Web of Science ®Google Scholar
• Cheung CHY, Juan HF. Quantitative proteomics in lung cancer. J Biomed Sci. 2017;24(1):37.
   PubMedGoogle Scholar
• Oberndorfer F, Müllauer L. Molecular pathology of lung cancer: current status and perspectives. Curr Opin Oncol. 2018;30(2):69–76.
   PubMed Web of Science ®Google Scholar
• Yu KH, Zhang C, Berry GJ, et al. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun. 2016;7(1):12474.
   PubMed Web of Science ®Google Scholar
• Piperdi B, Merla A, Perez-Soler R, et al. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 2014;74(4):403–413.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Doebele RC, Kerr KM, et al. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341–355.
   PubMed Web of Science ®Google Scholar
• Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52(1):103–109.
   PubMedGoogle Scholar
• Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28(1):e26–31.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–618.
   PubMed Web of Science ®Google Scholar
• Richardsen E, Uglehus RD, Due J, et al. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology. 2008;53(1):30–38.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132–5136.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113(6):1387–1395.
   PubMed Web of Science ®Google Scholar
• Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16):5220–5227.
   PubMed Web of Science ®Google Scholar
• Ito N, Suzuki Y, Taniguchi Y, et al. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res. 2005;25(3b):2027–2031.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559.
   PubMed Web of Science ®Google Scholar
• Wan Q, Tang J, Han Y, et al. Co-expression modules construction by WGCNA and identify potential prognostic markers of uveal melanoma. Exp Eye Res. 2018;166:13–20.
   PubMed Web of Science ®Google Scholar
• Tian Z, He W, Tang J, et al. Identification of important modules and biomarkers in breast cancer based on WGCNA. Onco Targets Ther. 2020;13:6805–6817.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Zhou R, Zhang J, Zeng D, et al. Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer. Cancer Immunol Immunother. 2019;68(3):433–442.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang E, Long J, et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 2019;110(5):1564–1572.
   PubMed Web of Science ®Google Scholar
• Zhao SG, Lehrer J, Chang SL, et al. The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst. 2019;111(3):301–310.
   PubMedGoogle Scholar
• Zheng Y, Tian H, Zhou Z, et al. A novel immune-related prognostic model for response to immunotherapy and survival in patients with lung adenocarcinoma. Front Cell Dev Biol. 2021;9:651406.
   PubMed Web of Science ®Google Scholar
• Fumet JD, Richard C, Ledys F, et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer. 2018;119(8):950–960.
   PubMed Web of Science ®Google Scholar
• Fu J, Bian M, Jiang Q, et al. Roles of aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007;5(1):1–10.
   PubMed Web of Science ®Google Scholar
• Lampson MA, Cheeseman IM. Sensing centromere tension: aurora B and the regulation of kinetochore function. Trends Cell Biol. 2011;21(3):133–140.
   PubMed Web of Science ®Google Scholar
• Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab. 2005;90(2):928–935.
   PubMed Web of Science ®Google Scholar
• Jha HC, Lu J, Saha A, et al. EBNA3C-mediated regulation of aurora kinase B contributes to epstein-barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases. J Virol. 2013;87(22):12121–12138.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhou J, Xu F, et al. High expression of aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancer. Int J Biol Markers. 2018;33(2):215–221.
   PubMed Web of Science ®Google Scholar
• Hayama S, Daigo Y, Yamabuki T, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res. 2007;67(9):4113–4122.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Liu XX, Li H, et al. Elevated mRNA levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis. Int J Med Sci. 2018;15(14):1676–1685.
   PubMed Web of Science ®Google Scholar
• Gujar AD, Yano H, Kim AH, et al. The CDC20-APC/SOX2 signaling axis: an achilles’ heel for glioblastoma. Mol Cell Oncol. 2016;3(3):e1075644.
   PubMed Web of Science ®Google Scholar
• Garg M, Maurya N. WNT/β-catenin signaling in urothelial carcinoma of bladder. World J Nephrol. 2019;8(5):83–94.
   PubMedGoogle Scholar
• Zhang Q, Huang H, Liu A, et al. Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells. EBioMedicine. 2019;42:397–407.
   PubMed Web of Science ®Google Scholar
• Chu Z, Zhang X, Li Q, et al. CDC20 contributes to the development of human cutaneous squamous cell carcinoma through the Wnt/β‑catenin signaling pathway. Int J Oncol. 2019;54(5):1534–1544.
   PubMed Web of Science ®Google Scholar
• Zhan T, Rindtorff N, Boutros M, et al. Wnt signaling in cancer. Oncogene. 2017;36(11):1461–1473.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shao H, Huang Y, et al. PLK1 phosphorylates mitotic centromere-associated kinesin and promotes its depolymerase activity. J Biol Chem. 2011;286(4):3033–3046.
   PubMed Web of Science ®Google Scholar
• Kline-Smith SL, Khodjakov A, Hergert P, et al. Depletion of centromeric MCAK leads to chromosome congression and segregation defects due to improper kinetochore attachments. Mol Biol Cell. 2004;15(3):1146–1159.
   PubMed Web of Science ®Google Scholar
• Howard J, Hyman AA. Microtubule polymerases and depolymerases. Curr Opin Cell Biol. 2007;19(1):31–35.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Cao Y, Reichelt U, et al. NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int J Cancer. 2010;127(2):381–393.
   PubMed Web of Science ®Google Scholar
• Bai Y, Xiong L, Zhu M, et al. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. Cancer Biomark. 2019;24(3):371–382.
   PubMed Web of Science ®Google Scholar
• Wieczorek M, Bechstedt S, Chaaban S, et al. Microtubule-associated proteins control the kinetics of microtubule nucleation. Nat Cell Biol. 2015;17(7):907–916.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li DP, Shen N, et al. TPX2 promotes migration and invasion of human breast cancer cells. Asian Pac J Trop Med. 2015;8(12):1064–1070.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang H, Zhang G, et al. Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer. Biochem Biophys Res Commun. 2018;507(1–4):74–82.
   PubMed Web of Science ®Google Scholar
• Zhu H, Liu J, Feng J, et al. Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer. Medicine (Baltimore). 2020;99(49):e23554.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.
   PubMed Web of Science ®Google Scholar